Huang ES, Basu A, O'Grady M, et al: Projecting the future diabetes population size and related costs for the US. Diabetes Care 32: 2225, 2009.
Snyder RJ, Kirsner RS, Warriner RA, et al: Consensus recommendations on advancing the standard of care for treating neuropathic foot ulcers in patients with diabetes. Ostomy Wound Management 56(suppl 4): S1, 2010.
Boulton AJ, Kirsner RS, Vileikyte L: Clinical practice. Neuropathic diabetic foot ulcers. N Engl J Med 351: 48, 2004.
Margolis D, Kantor J, Berlin J: Healing of neuropathic ulcers receiving standard treatment: a meta-analysis. Diabetes Care 22: 692, 1999.
Shores JT, Gabriel A, Gupta S: Skin substitutes and alternatives: a review. Adv Skin Wound Care 20: 493, 2007.
Niknejad H, Peirovi H, Jorjani M, et al: Properties of the amniotic membrane for potential use in tissue engineering. Eur Cell Mater 15: 88, 2008.
Bennett JP, Matthews R, Faulk WP: Treatment of chronic ulceration of the legs with human amnion. Lancet 1: 1153, 1980.
Baradaran-Rafii A, Aghayan H, Arjmand B, et al: Amniotic membrane transplantation. Iran J Ophthalmic Res 2: 58, 2007.
Adly OA, Moghazy AM, Abbas AH, et al: Assessment of amniotic and polyurethane membrane dressings in the treatment of burns. Burns 36: 703, 2010.
Tao H, Fan H: Implantation of amniotic membrane to reduce postlaminectomy epidural adhesions. Eur Spine J 18: 1202, 2009.
John T: Human amniotic membrane transplantation: past, present, and future. Ophthalmol Clin North Am 16: 43, 2003.
Akle C, Adinolfi M, Welsh K, et al: Immunogenicity of human amniotic epithelial cells after transplantation into volunteers. Lancet 2: 1003, 1981.
Hao Y, Ma DH, Hwang DG, et al: Identification of antiangiogenic and antiinflammatory proteins in human amniotic membrane. Cornea 19: 348, 2000.
King AE, Paltoo A, Kelly RW, et al: Expression of natural antimicrobials by human placenta and fetal membranes. Placenta 28: 161, 2007.
Gruss JS, Jirsch DW: Human amniotic membrane: a versatile wound dressing. Can Med Assoc J 118: 1237, 1978.
Neuropathic foot ulcers are a common complication in patients with diabetes. These ulcers are often slow to heal and can lead to infection, further tissue destruction, osteomyelitis, and amputation. These patients pose a challenge to clinicians who must determine the best treatment options while balancing the risks, benefits, and costs. Conservative therapies often present disappointing results, and a number of newer “biologic bandages” have been developed to better assist the healing process. We describe results from diabetic patients with neuropathic foot ulcers treated with a new amniotic membrane–based allograft.